Literature DB >> 17367905

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

S Vincent Rajkumar1, Martha Q Lacy, Robert A Kyle.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic disorders characterized by monoclonal plasma cell proliferation in the bone marrow in the absence of end-organ damage. Updated diagnostic criteria for these disorders, risk-stratification models to determine prognosis, and the current management of these two entities are discussed in this review.

Entities:  

Mesh：

Year:  2007        PMID： 17367905     DOI： 10.1016/j.blre.2007.01.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN： 0268-960X            Impact factor:   8.250


  18 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 2.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

3.  Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition.

Authors:  G W Gordon; J Monge; M B Channon; Q Wu; J L Skulan; A D Anbar; R Fonseca
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

4.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Emily A Barber; Layla M Saleh; Adriana Zingone; Azam Ghafoor; Rene Costello; Yong Zhang; Roger J Kurlander; Neha Korde; Aldo M Roccaro; Irene M Ghobrial; Ola Landgren; Katherine R Calvo
Journal:  J Mol Diagn       Date:  2015-09-30       Impact factor: 5.568

5.  A case study progression to multiple myeloma.

Authors:  Mary Ann Yancey; Adam J Waxman; Ola Landgren
Journal:  Clin J Oncol Nurs       Date:  2010-08       Impact factor: 1.027

Review 6.  Development of early treatment strategies for high-risk myeloma precursor disease in the future.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 7.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Authors:  Adriana Zingone; W Michael Kuehl
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 9.  Staging and prognostication of multiple myeloma.

Authors:  Rafael Fonseca; Jorge Monge; Meletios A Dimopoulos
Journal:  Expert Rev Hematol       Date:  2014-02       Impact factor: 2.929

10.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.